Publicaciones en colaboración con investigadores/as de Champalimaud Foundation (17)

2024

  1. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology

2023

  1. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 2, pp. 198-205

2022

  1. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

2021

  1. Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

    JAMA Oncology, Vol. 7, Núm. 4, pp. 573-584

  2. Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8-11, 2020

    Breast Care

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

  4. Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1875, Núm. 1

2020

  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649

  2. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

    ESMO Open, Vol. 5

  3. Enhancing global access to cancer medicines

    CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124

  4. HER2-Low breast cancer: Pathological and clinical landscape

    Journal of Clinical Oncology, Vol. 38, Núm. 17, pp. 1951-1962

  5. Pembrolizumab for early triple-negative breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 9, pp. 810-821

2019

  1. Breast cancer

    Nature Reviews Disease Primers, Vol. 5, Núm. 1

  2. Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    Annals of Oncology, Vol. 30, Núm. 3, pp. 365-373

2018

  1. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657

  2. Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?

    Breast, Vol. 41, pp. 133-135

2017

  1. Research needs in breast cancer

    Annals of Oncology, Vol. 28, Núm. 2, pp. 208-217